Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA – Free Report) – Equities researchers at HC Wainwright boosted their FY2029 earnings per share (EPS) estimates for Innate Pharma in a research report issued to clients and investors on Monday, September 21st. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of $0.30 for the year, up from their previous forecast of $0.23. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Innate Pharma’s current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for Innate Pharma’s FY2030 earnings at $0.61 EPS.
IPHA has been the topic of several other research reports. BTIG Research reaffirmed a “buy” rating and set a $9.00 target price on shares of Innate Pharma in a research note on Thursday, September 17th. UBS Group reissued a “buy” rating on shares of Innate Pharma in a research report on Tuesday, August 11th. Weiss Ratings upgraded shares of Innate Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, June 26th. Citigroup upgraded shares of Innate Pharma from a “buy” rating to an “outperform” rating in a research report on Tuesday, August 11th. Finally, Leerink Partners raised shares of Innate Pharma from a “market perform” rating to an “outperform” rating and set a $4.00 target price for the company in a research note on Tuesday, August 11th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $6.67.
Innate Pharma Price Performance
NASDAQ:IPHA opened at $1.76 on Tuesday. The business’s fifty day moving average price is $1.98 and its 200 day moving average price is $1.75. Innate Pharma has a 1-year low of $1.17 and a 1-year high of $2.71.
More Innate Pharma News
Here are the key news stories impacting Innate Pharma this week:
- Positive Sentiment: Zacks upgraded IPHA to a Buy. The upgrade to Zacks Rank #2 reflects growing optimism about Innate Pharma’s earnings prospects and could attract additional investor interest. Innate Pharma Upgraded to Buy: Here’s What You Should Know
- Positive Sentiment: HC Wainwright raised its earnings forecasts through 2028. The analyst now expects losses of $0.53 per share in fiscal 2026, $0.45 in fiscal 2027 and $0.08 in fiscal 2028, compared with previous estimates of $0.79, $0.59 and $0.15, respectively. The narrowing losses suggest improving confidence in the company’s path toward profitability; HC Wainwright maintains a Buy rating. HC Wainwright Earnings Estimates for Innate Pharma
- Positive Sentiment: Longer-term profit estimates also increased. HC Wainwright lifted its fiscal 2029 EPS forecast to $0.30 from $0.23 and its fiscal 2030 forecast to $0.61 from $0.58, indicating expectations for sustained profitability after the projected loss-making period. Long-Term Innate Pharma Earnings Estimates
- Positive Sentiment: Innate Pharma closed its Sobi deal. The transaction provides a new funding development that may help keep the company’s drug trials on track and reduce near-term financing concerns. Investors will likely focus on the size, timing and durability of the funding benefit. Innate Pharma Closes Sobi Deal
Innate Pharma Company Profile
Innate Pharma SA is a biotechnology company headquartered in Marseille, France, focused on developing immunotherapies for cancer. Founded in 1999, the company uses its expertise in the biology of natural killer cells and other components of the innate immune system to develop antibody-based treatments designed to help the immune system recognize and attack cancer cells.
Innate Pharma’s pipeline includes lacutamab, an investigational antibody targeting KIR3DL2 for certain forms of cutaneous T-cell lymphoma and other T-cell malignancies.
Read More
- Five stocks we like better than Innate Pharma
- Chips to Bots: Qualcomm’s Agentic AI Breakout
- Ciena Fell 40%—Now One Analyst Sees 50% Upside
- Energy Transfer Taps the AI Power Boom
- Viking’s Obesity Edge May Be Staying Power, Not Weight Loss
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
